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Evropská léková agentura (European Medicine Agency; EMA) a Úřad pro 
potraviny a léčiva (Food and Drug Administration; FDA) kladou důraz na 
prozkoumání permeability léčiv skrz biologické membrány a jejich interakcí 
s ABC transportéry, které jsou fyziologickými bariérami produkovány, ať už 
v rámci preklinického testování léčiv nebo u molekul, které jsou již klinicky 
užívány, avšak chybí u nich důkazy o těchto parametrech. Cílem této práce bylo 
zhodnotit schopnost několika experimentálních inhibitorů butyrylcholinesterázy, 
které byly vytvořeny za účelem léčby demence, prostupovat skrze 
hematoencefalickou bariéru a objasnit význam transportních proteinů ABC 
rodiny (ATP-binding cassette/ABC transporters) v tomto přenosu.
Při této práci byla využita in vitro obousměrná transportní studie přes 
monovrstvy tvořené polarizovanými a vysoce diferenciovanými Caco-2 
buňkami. Hodnoty permeability získané z těchto měření byly podobné 
hodnotám několika běžně užívaných léčiv pro terapii CNS nemocí (např. 
antidepresiv, antiepileptik). Molekuly také vykazovaly hodnotu efluxního poměru 
(basolaterální – apikální/ apikální – basolaterální) přibližně jedna, což 
naznačuje žádný či zanedbatelný vliv aktivního transportu. 
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European Medicine Agency (EMA) and Food and Drug Administration 
agency (FDA) emphasise drug membrane permeability and drug-drug 
interactions on ABC transporters expressed in physiological barriers should be 
investigated for compounds in preclinical studies or for those already clinically 
used but evidence free. In this work we aimed to assess the capability of 
several experimental butyrylcholinesterase inhibitors that had been designed to 
treat dementia to permeate blood-brain barrier and to elucidate role of ATP-
binding (ABC) cassette transporters in this transport.
For this purpose, we employed in vitro bidirectional transport study 
across monolayers formed by polarized and highly differentiated Caco-2 cells. 
The permeability values gained from measurements were similar to values of 
several commonly used drugs for treatment of CNS disorders (e.g. 
antidepressants, antiepileptics). In addition, the compounds showed values of 
efflux ratio (basolateral-to-apical/apical-to-basolateral) approximately one which 
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1. Introduction
With the aging population, the neural diseases affecting the central 
nervous system (CNS), such as dementia, are steadily increasing. 
Therefore, there is a need for development of neuropharmaceuticals, which 
are capable of treating or at least slowing down the neural damage. To 
reach site of actions neuropharmaceuticals must pass through the blood-
brain barrier (BBB). In vitro cell-based models represent a useful screening 
tool to anticipate drug BBB permeability and interactions with drug 
transporters (Vastag et al. 2011).
2. Theoretical	part
2.1.Cholinesterase	inhibitors
Alzheimer’s disease is one of most prevalent types of dementia in elderly 
population (around 60 – 80% cases). As the condition progresses, due to 
degeneration of neural cells followed by decrease of cholinergic 
transmission, thus cognitive function and memory of patient are impaired. 
Unfortunately, only symptomatic treatment currently exists targeting 
cholinesterase, an enzyme responsible for acetylcholine (ACh) degradation
and in more severe cases also NMDA (N-methyl-D-aspartate) receptors.
Human brain has two types of cholinesterase: acetylcholinesterase 
(AChE), which is more substrate specific and highly efficient, and 
butyrylcholinesterase (BChE). In healthy person both enzymes contribute to 
ACh biodegradation with AChE representing around 80% of total activity. As 
the illness progresses, AChE activity gradually decreases, while BChE 
activity remains unchanged or is even increased. Furthermore, due to the 
presence of BChE in neuritic plaques, it may play a role in formation of β-
amyloid (Giacobini 2004).
Currently used drugs for treatment of Alzheimer’s disease either 
specifically target AChE (donepezil, galantamine) or bind to AChE and 
BChE in equal manner (e.g. rivastigmine). In more severe cases, there may 
be a need for selective inhibitors of BChE due to its steadily increasing
importance in ACh metabolism in central nervous system (Lane et al. 2006). 
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During the development of new potential drugs, many preclinical 
experimental procedures have to be conducted, including those assessing 
the ability of molecule to penetrate physiological barriers, which in case of 
BChEi also means transport through BBB.
2.2.The blood-brain	barrier
The BBB consists of endothelial cells of microvessels, basal lamina, 
pericytes and astrocyte end-feet. Endothelial cells forming the BBB are 
connected with tight junctions and lack fenestrations. Tight junctions (along 
with the adherens junctions) form the junction complex, which restricts the 
paracellular transport of molecules (Ballabh et al.2004).
BBB regulates the influx and efflux of various substances into the brain 
thus maintains its stable environment and functionality. Large surface area 
of BBB (approximately 12-20 m2 /1.3 kg brain) and short diffusion distance 
from capillaries to neural cells (< 10-15 µm) make it important transport 
pathway into brain tissue (Abbot 2005).
The BBB is not present in every part of the brain. The circumventricular 
organs, i.e. area postrema or neurohypophysis, have capillaries with 
fenestrations, which allow those parts of central nervous system to 
communicate with the rest of body by detecting signals from peripheral 
tissues (i.e. inflammatory markers like interleukins) or contribute on 
maintaining the homeostasis (via hormones) (Ganong 2000)
2.3. Mechanism	of	transport	across blood-brain	barrier
The junction complex ensuring the tightness of the BBB seals the 
paracellular pathway, restricting movement of polar molecules through the 
intercellular space of endothelium and forcing the compounds to take the 
trancellular route. 
Large molecules (i.e. polypeptides or proteins) may be carried across the 
BBB using vesicles, which can be formed by two mechanisms. The first one, 
demanding specific interaction of membrane receptor with
the macromolecule is called receptor mediated transcytosis (RMT). 
The latter one, adsorptive mediated transcytosis (AMT), utilizes noncovalent 
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bond between positively charged molecules and negatively charged 
endothelial glycocalyx (Abbot 2005).
Small molecules like oxygen or carbon dioxide can diffuse freely across 
the lipid bilayer, ensuring the oxidative metabolism and regulation of pH in 
brain. Nutrients, which are able to move via the paracellular route in 
peripheral tissues, are prevented to use this way of permeation across the 
BBB. In order to ensure the delivery of those compounds into CNS, BBB 
expresses several uptake transmembrane transporters that are able to 
transfer molecules of MW <1000. Nowadays, more than 20 specific carriers
have been identified for endogenous molecules including glucose, amino 
acids, nucleosides, nucleobases etc. Carriers may function independently on 
energy mediating facilitative diffusion driven by the concentration gradient 
(energy independent, e.g. GLUT-1, nucleoside transporters), while some 
transport their substrates only uni-directionally, often against concentration 
gradient, which requires direct supply of energy in form of ATP (primary 
active transport) or coupling to symport or antiport of another molecule 
(secondary active transport). The localization of carriers can be either on
apical or basal side of barrier or even on both (Abbot 2005, Pardridge 2007).
Primary active transporters are predominantly represented by family of 
ATP-binding cassette (ABC) efflux transporters with broad substrate 
spectrum that pump compounds out of the endothelial cells. The most widely 
expressed are P-glycoprotein (P-gp, ABCB1), the Multidrug Resistance-
Related Proteins (MRPs, ABCC) and the Breast Cancer Resistance Protein 
(BCRP, ABCG2). These transporters are able to reduce the passage of their 
substrates (either drugs or toxic compounds) across membranes and thus 
protect sensitive tissue of brain (Pardridge 2007).
2.4.P-glycoprotein
As a member of ABC family, P-gp encoded by ABCB1/MDR1 gene in 
mammals, is found in many different body tissues (mostly on apical side of 
membrane), especially in those forming physiological barriers (i.e. renal 
tubules, hepatocytes, intestine or BBB), and plays important part in 
pharmacokinetics of several (mostly lipophilic) drugs. Efflux mediated by P-
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gp is also frequent cause of multi-drug resistance of various tumour cells to 
anticancer drugs (Adachi et al. 2001, Zhou 2008)).
P-gp interacts with wide range of compounds, which differ in structure 
and molecule size (from small molecules to macromolecules like peptides).
Activity of P-gp can be inhibited by competitive binding of substrates
(verapamile, tamoxifen) or by drugs blocking ATP hydrolysis (steroids, 
disulfiram), or induced by compounds causing higher transcription activity
(phenytoin) (Sharom 2011, Zhou 2008).
2.5.Breast	Cancer	Resistance	Protein
Another member of ABC family is BCRP, which was discovered later 
than P-gp and was first cloned from doxorubicin-resistant breast cancer cell 
line. BCRP can not only be found in breast cancer, localization is similar to 
P-gp. BCRP is mostly expressed in biological barriers as well as in 
tumorigenic pathological tissues. 
BCRP also plays role in drug pharmacokinetics in similar way to P‑gp.
BCRP has wide substrate specifity, frequently overlapping with P-gp,
recognizing molecules both positively and negatively charged. Activity of this 
efflux transporter can also be modulated like P-gp, especially in terms of 
inhibition, which is sought in order to increase the drug disposition in 
targeted area. (Štaud, Pávek 2005)
2.6.In	vitro	models	for	blood-brain barrier permeability
Predicting the level of brain penetration is important part in drug 
development. Thus, there are several models used to simulate BBB 
permeability; i.e. in silico prediction, parallel artificial membrane permeability 
assay (PAMPA), cell-culture based models and animal models (Vastag, 
Keserü 2009)
PAMPA was first developed to estimate the rate of gastrointestinal 
absorption and was furthermore employed as means of permeability 
assessment early in the drug discovery process by pharmaceutical industry. 
It involves use of artificial, lipid infused membrane, therefore is focused only 
on prediction of passive transport due to the lack of proteins integrated in 
cell membrane. However, by modifying the lipid composition of membrane, 
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one can achieve a system capable of recognizing the compounds as BBB 
permeable or non-permeable, which correlates well with cell-based models
(Mensch et al. 2010, Vastag, Keserü 2009).
Favourable tools to anticipate the BBB penetration are cell-based in vitro
models due to the higher complexity of information (than PAMPA can 
provide) regarding the passive and active transport (Hellinger et al. 2012). 
To make the cell models viable for BBB permeability prediction, there are 
two critical features to follow:
a) presence of functional efflux transporters, especially P-gp, can 
furthermore make prediction of permeability more accurate. P-gp is 
involved in brain distribution of a drug and can severely reduce the 
rate of penetration. P-gp functionality can be described as the fold 
difference of basolateral-to-apical and apical-to-basolateral drug 
transport across monolayer formed by polarized cells
b) absence of leakage; intercellular integrity of cells can be measured 
with transendothelial electrical resistance (TEER) or by tracer 
permeability. The threshold value of TEER should be 150-200 Ωcm2
(although the brain endothelium TEER is greater than 1000 Ωcm2) to
consider the data gained from the model as reliable (Deli et al. 2005).
Permeability of solutes through paracellular pathway is estimated with 
fluorescent or isotope markers (e.g. fluorescein, Lucifer yellow)
(Vastag et al. 2011).
There are two types of in vitro cell culture models used to predict BBB
permeability for drugs: brain capillary endothelial cell-based and epithelial 
cell-based BBB models (Hellinger et al. 2012)
2.7.Endothelial	cell	culture	models
Endothelial cell culture models are based on cells of brain capillary
endothelium cultured alone or along with astrocytes and/or pericytes. These 
include primary cell cultures such as porcine brain microvessel endothelial-
cell model, bovine brain capillary endothelial-cell model and co-culture of rat 
brain capillary model with astrocytes and pericytes (Zhang et al. 2006; Culot 
et al. 2008; Nakagawa et al. 2009).
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Other types of endothelial cells include immortalized brain cell lines, 
which are easier to handle and are less expensive. However, there have 
been some drawbacks, which make them less suitable for drug permeability 
analysis, e.g. incomplete tight junctions (Vastag, Keserü 2009). 
Brain capillary cells are considered to imitate best the properties of BBB 
due to the lipid composition of membrane, complexity of tight junctions and 
composition of BBB enzymes (Dehouck et al. 1994). On the other hand, due 
to high cost and intensive handling, these models are not suitable for 
industrial scale.
2.8.Epithelial cell	culture	models
Surrogate BBB models, Madin-Darby Canine Kidney (MDCK) and human 
colon carcinoma (Caco-2) cell lines, have showed highly comparable in vitro
- in vivo BBB permeability correlations, despite their different origin, similar
transporter spectrum and membrane composition (Garberg et al. 2005).
2.8.1. Human	colon	carcinoma	cell	line
Caco-2 cell line originates from human colon adenocarcinoma. Despite 
being derived from large intestine, Caco-2 cells exhibit many features similar 
to cells of small intestine, such as microvilli, intercellular junctions, enzymes, 
uptake and efflux transporters (Ward et al. 2000). This model represents a 
useful tool for investigation of transcellular and paracellular permeability, 
vesicular transport, active transport, facilitated transport and efflux systems. 
Therefore it is commonly used for prediction of intestinal absorption of drug 
after oral administration. Best correlation is gained for molecules transported 
mostly by passive diffusion and minimally influenced by active uptake 
(Artursson et al. 2012). Due to the expression of efflux transporters similar to 
BBB (Table 1), the Caco-2 cell line results obtained can be also extrapolated 
to BBB (Hellinger et al. 2012).
There are several reasons, why the Caco-2 cell line is widely used. They 
are easily cultivated and the growth can be performed on many plastic 
surfaces, nitrocellulose filters and on Transwell® membrane made from 
polycarbonate. The cultivation takes about 21 days until the cells are 
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polarized and fully differentiated. When growing, the cells display the contact 
inhibition, thus resulting in monolayer formation (Ward et al. 2000).
Integrity check by TEER results in different values depending on the 
passage number and equipment used for measurement (Briskey-Anderson 
et al. 1997). Another option is assaying the monolayer permeability for 
solutes using paracellular transport (e.g. mannitol or fluorescein). The 
epithelial permeability of Caco-2 cell monolayers appears to be close to 
permeability of human or rat intestinal epithelia regarding the junction 
complex throughput (Artursson et al. 2012).  
Transporters/Enzymes


































Table 1: Comparison of several common transporters and enzymes involved in 
drug transport and metabolisation in brain capillary endothelium and Caco-2 cell 




The objective of this thesis was to determine the permeability of several 
butyrylcholinesterase inhibitors (BChEi) with the use of Caco-2 cell 
monolayers and to find out any signs of excessive active transport in either 
direction across the cell monolayers. 
4. Materials	and	methods
4.1.Materials
Complete growth medium used for cultivation consisted of Dulbecco’s 
Minimum Essential Medium (DMEM; Sigma-Aldrich Co., USA), 20% FBS
(Fetal Bovine Serum; Gibco®, USA), 1% Penicillin/Streptomycin (Sigma 
Aldrich Co., USA) and 1% L-glutamine (Sigma Aldrich Co., USA). DPBS 
(Dulbecco’s Phosphate Buffer Saline; used for rinsing the tissue) and Trypan 
Blue solution (used as staining) originated from Sigma Aldrich Co. (USA). 
TrypLETM Express Enzyme used for detaching the cells from surface of 
culture flasks came from Gibco® (Grand Island NY, USA).
All experiments were performed using 10mM solution of glucose in 
Ringer for the basolateral side of membrane and 10mM solution of mannitol 
in Ringer for the apical side. The Ringer solution consisted of 140.6 Na+,5
K+, 1.2 Ca2+, 1.2 Mg2+, 121.8 Cl−, 25 HCO3
−, 0.4 H2PO4
−, 1.6 HPO4
2− in mM 
(Žakelj et al. 2004)
Compounds tested in the experiments were provided by University of 
Ljubljana, Faculty of Pharmacy (Table 2).
15
Table 2: The list of tested compounds with corresponding labels and molecular 
weight.
Structure













Caco-2 cells used for experiments were obtained from American Tissue 
Culture Collection (ATCC) HTB-37. After unfreezing and removing the 
cryoprotectant (DMSO) by adding 8ml of medium and centrifugation (800 
RPM, 8 min), the cells were resuspended in appropriate amount of growth 
medium, transferred in culture flask (TPP Techno Plastic Products, 
Trasadingen, Switzerland) and put into incubator (37°C, 5% CO2). The 
medium was changed every two days. 
After reaching 80-90% confluence, which occurred usually once in seven 
days, the medium was removed from the flask and the cells were rinsed with 











the flask was incubated at 37°C for 1 minute. Next, the flask was shaken in 
order to detach the cells from the surface. To interrupt the enzymatic action 
of trypsine, 5ml of growth medium were added. The suspension was 
centrifuged (800 RPM, 8 min). The supernatant was removed and the cells 
were resuspended in 3ml of fresh medium and counted. Counting was 
performed by mixing 10µl of cell suspension and 40µl of trypan blue solution 
and transferring 10µl of the mixture on hemacytometer.
Cells (passage 18-25) were seeded on 12 well plates polycarbonate 
Transwell® Permeable Support (Corning Incorporated, Tewksbury, USA) at 
density 0.1 x 106/ml) reaching 0.5ml of medium in upper, apical side. Then 
1.5ml of medium was added to lower, basolateral (Figure 1). Cells were 
grown for 3 weeks with the medium changed every two days.
Figure 1: Schematic illustration of an epithelial monolayer grown on a permeable 
support, e.g. Transwell® (Neuhoff 2005)
4.3.Monolayer	integrity	check
The integrity of monolayers on inserts was checked by TEER using 
electrode Millipore Millicell® against blank wells filled with medium. Next, the 
resistance of monolayer was multiplied by effective growing area (1.1 cm2) 
and expressed as Ω·cm2. The average TEER value was 727 ± 96 Ω·cm2. 
The TEER was measured before the experiment.
Fluorescein (FLU), added to the donor solution, was used to check cell 
monolayer integrity after experiment. From samples collected in different 
intervals (every 20 minutes up to 120 minutes), 40 µl were transferred to 
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microtiter plate and supplemented with 160 µl of 0.025M NaOH. The 
samples were analyzed on fluorescence and UV well plate reader Tecan 
Safire2™. Then the permeability was calculated from calibration curve and
should not exceed 1·10-6 cm·s-1.
4.4.In	vitro	transport	studies
Prior to experiment, solutions used for transport experiments were 
prepared. Donor solutions contained 100µM of tested compound, 20µM of 
FLU and 10mM of either mannitol for apical to basolateral transport (AP-BL) 
or glucose for basolateral to apical experiment (BL-AP). Acceptor solutions 
were composed of either 10mM mannitol for apical compartment or 
10mM glucose for basolateral compartment 
All basolateral solutions, both for apical to basolateral transport and vice 
versa, were added to plates and pre-warmed in Labnet Vortemp 56 EVC 
Shaking Incubator (37°C, 5% CO2, 20 RPM). Inserts with the cell monolayer 
were disposed of growth medium and rinsed with Ringer solution (pH 7.4). 
Next, apical solutions were pipetted to apical side of inserts and those were 
transferred to pre-incubated wells. 
The samples from acceptor site were collected every 20 minutes for 
2 hours, 100µl from apical side for BL-AP measurements and 300µl from 
basolateral side for AP-BL measurements, then the missing volume 
was refilled with either mannitol or glucose solution, depending on side from 
which the samples were taken. In the end of experiment, samples from 
donor solutions were taken and diluted twentyfold (Žakelj et al. 2004).
4.5.HPLC
All samples were analyzed with an Agilent 1100 series HPLC system 
(degasser, binary pump, temperature-regulated well plate sampler, column 
thermostat and UV-VIS diode array detector) using Zorbax Eclipse XDB-C18 
column (4.6 x 75mm, 3.5µm) at 55°C. The mobile phase was composed of 
diluted phosphoric acid (pH 2.5) and acetonitrile (ACN). Linear gradient was 




The apparent permeability coefficient (Papp) was calculated using 








where dQ/dt is the amount, which diffused through the membrane 
per time unit, A is the surface area of monolayer (1.12 cm2) and C0 is the 
initial concentration of compound in donor solution (100µM).
All data obtained from HPLC analysis were processed using calibration 
curve for each compound. Calibration curves with Pearson coefficient 
with at least R2= 0.963 were used for calculations. Results are presented as 
means ± standard deviation (SD) of at least four parallel permeability 
measurements. 
Data were statistically evaluated using non-parametric Mann-Whitney 
test with two-tailed P values using GraphPad Prism 5.0 software.
5. Results
Permeability coefficients of five tested compounds through the Caco-2 
cell monolayers were calculated in AP-BL and BL-AP directions, then efflux 
ratio was determined for each compound.
5.1.HPLC	methods	development
First, using 2µM solution of compound dissolved in water, all tested 
compounds underwent HPLC-UV analysis using gradient elution with ACN
percentage steadily increasing in order to determine approximate ratio of 
mobile phase components. Next, using isocratic elution ideal H3PO4: ACN 
ratio was established to lower the retention time, but not to affect 
chromatogram resolution. Wavelength at which the substances absorbed 
the most was also acquired. The method setup was performed before the 
measuring of permeability. The methods used for each compound are listed 
in Table 3.
20
Table 3: The composition of mobile phase with corresponding percentage, 










GUK-901 63 37 231 1.38
GUK -982 66 34 224 1.45
GUK - 987 79 21 224 1.03
GUK -1007 67 33 234 1.60
GDK - 375 83 17 251 1.20
SDH - 381 79 21 240 2.18
5.2.Transport	studies	of	butyrylcholinesterase	inhibitors
Nearly every compound, that the experiments were conducted with,
showed transport across cell monolayers, but not affected by active 
transport (Figure 2). There was slight increase in amount transported from 
basolateral to apical compartment compared to opposite direction (Table 4);
however the efflux ratio, which was acquired as a quotient of Papp (BL-AP)/Papp
(AP-BL) and ranged from 0.97 to 1.65, showed no considerable efflux 
transporter involvement. Average results of measurements performed are 
shown in Table 5 Table 4and illustrated in Figure 3.
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Figure 2: Graphic representation of cumulative amount curves over time; blue line 
represents amount of selected compounds transported across monolayer in apical-




















































































SDH - 381 AP-BL
BL-AP
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Table 4: Apparent permeability coefficient values for each measurement and filter 
(Papp; cm · s
-1 x 10-6). In the case of BL-AP direction measurements for SDH-381, 
the sixth filter used for this compound showed low TEER value before the 
experiment, and the fluorescein check confirmed the leakiness of that monolayer, 
therefore it was not included in the average result.
Papp
GUK -901 GUK-982 GUK-987 GDK-375 SDH-381
No. AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP
1 45.55 28.38 33.68 45.60 28.63 40.22 32.54 50.54 40.46 43.21
2 36.88 26.59 36.77 48.87 26.86 46.82 36.07 52.53 39.00 45.33
3 34.90 34.41 36.44 50.35 28.89 47.49 36.36 49.51 58.21 47.50
4 21.06 29.75 33.63 43.66 27.35 39.52 36.70 54.73 40.66 47.21
5 21.44 29.16 34.51 50.10 27.47 50.41 38.92 56.13 47.68 46.80
6 19.84 26.53 34.92 52.25 28.83 52.21 31.42 55.64 36.82 108.12
Table 5: Results of transport experiments showing average apparent permeability 
(Papp; cm · s
-1 x 10-6) for both directions with corresponding standard deviation (SD; 
n=6, for SDH-381 in BL-AP direction n=5) both in absolute and relative values 
(RSD; %). Efflux ratio between average BL-AP and AP-BL Papp values also 
included. 
AP-BL BL-AP





29.95 10.67 35.64 29.14 2.90 9.94 0.97
GUK-
982
34.99 1.35 3.86 48.47 3.23 6.66 1.39
GUK-
987
28.00 0.88 3.16 46.11 5.22 11.32 1.65
GDK-
375
35.34 2.81 7.95 53.18 2.76 5.18 1.50
SDH-
381
43.80 7.94 18.13 46.01 1.78 3.86 1.05
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Figure 3: Graphic representation of average Papp values for both directions across 
Caco-2 cell monolayers. Values gained were almost equivalent for AP-BL and BL-
AP transport. Each bar indicates mean ± SD (n=6); ns p > 0.05, ** p ≤ 0.01.
5.3.Monolayer	tightness	fluorescein	measurements
The simultaneous monolayer leakiness check conducted using 
fluorescein as marker showed no extreme values of permeability (Papp = 5.03 
± 2.48 ·10-7 cm·s-1; Table 6). However, the apparent permeability values 
gained from BL-AP transport experiments exceeded the opposite direction 
measurement’s values by one order of magnitude. Therefore, an experiment 
was carried out to discover possible influence of tested compounds on 
transport of fluorescein across the Caco-2 cell monolayers.
In this experiment, the apparent permeability of fluorescein alone and 
with GUK-987 as model compound either on apical or basolateral side was 
being determined using the same conditions as for previous bidirectional 
measurements.
After calculating the apparent permeability coefficient and efflux ratio, the 
results showed that the amount transported in BL-AP direction with GUK-
987 on either side greatly exceeds the amount of FLU transported in same 








AP -BL BL-AP AP -BL BL-AP AP -BL BL-AP AP -BL BL-AP AP -BL BL-AP














** ** ** ns
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Table 6: Apparent permeability coefficient values of fluorescein for each 
measurement and filter (Papp; cm · s
-1 x 10-6). Numbers of filters correlate with Table 
3. It is noticeable how the transport from basolateral side in the presence of several 
compounds is highly exceeding the transport in opposite direction.
FLU Papp
GUK -901 GUK-982 GUK-987 GDK-375 SDH-381
No. AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP AP-BL BL-AP
1 0.06 0.84 0.07 1.04 0.09 0.97 0.06 0.34 0.14 0.29
2 0.09 2.52 0.04 0.98 0.12 1.43 0.07 0.44 0.15 0.45
3 0.05 0.91 1.18 1.07 0.09 1.31 0.05 0.28 0.14 0.57
4 0.10 0.77 0.08 1.07 0.32 1.24 0.07 0.32 0.08 0.47
5 0.10 0.97 0.08 1.25 0.21 1.36 0.07 0.38 0.13 0.43
6 0.10 0.73 0.22 3.94 0.17 1.40 0.06 0.35 0.17 42.88
Table 7: Results of fluorescein transport experiment showing average apparent 
permeability (Papp; cm · s
-1 x 10-6) for both directions (with and without GUK-987)
with corresponding standard deviation (SD; n=4) both in absolute and relative 
values (RSD; %). Efflux ratio between average BL-AP and AP-BL Papp values also 
included.
AP-BL BL-AP
Label Papp SD RSD Papp SD RSD
Efflux 
ratio








0.11 0.02 13.44 1.25 0.15 12.04 10.92
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Figure 4: Graphic representation of average Papp values for FLU without GUK and 
with GUK on either apical or basolateral side, including both directions of FLU 
diffusion across Caco-2 cell monolayers. BL –AP values gained from experiments 
with GUK present on either side highly exceed those gained from both AP-BL 
transport measurements and measurements without GUK. Each bar indicates 
mean ± SD (n=4); * p ≤ 0.05
5.4.GUK-1007	transport	measurement
Compound labelled GUK-1007 was excessively metabolised and only 
very limited amount was able to permeate across the monolayer in 
unchanged form. HPLC-UV analysis (Figure 5) discovered that no significant 
amount passed through in either direction. Therefore the samples were also 
analyzed by LC-MS (MS data not shown). This analysis resulted in recovery 
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Figure 5: HPLC-UV chromatograms depicting GUK-1007 calibration sample (the 
former one) and GUK-1007 acceptor side sample (the latter one). There is small 
amount of parent compound noticeable in acceptor side sample; however 
compared to the metabolites it is negligible.











































The reason for utilization of Caco-2 cell line, which is commonly used for 
prediction of intestinal absorption, as a model for BBB permeability and 
active efflux has risen from the properties of the cells. Although its origin
differs from BBB, due to presence of tight junctions and limitation of 
paracellular transport, the permeability for compounds transported can be 
comparable to the permeability of brain capillary endothelial models, which 
are most reliable in the manner of data gained (Vastag, Keserü 2009). Caco-
2 cells reveal certain disadvantages. First, the growth rate is three-time 
slower compared to MDCK, other type of cell line for BBB permeability 
prediction. Furthermore, the expression of efflux transporters may not reach 
the levels in BBB (use of transfected models, such as VB-Caco-2 or MDCK-
MDR1 may be more suitable) (Hellinger et al 2012). On the other hand, 
Caco-2 cell line is well established in vitro approach to predict intestinal 
absorption and role of transporters as well. In comparison to MDCK cells, 
when cultured properly, Caco-2 cells show more reliable level of growth in 
manner of monolayer cohesion (Volpe 2008).
In order to identify the compound as a substrate of apical efflux 
transporters (P-glycoprotein, BCRP etc.) with clinical impacts, the efflux ratio 
(coefficient of permeability B→A to A→B direction) value should be equal or 
higher than two (Sun et al. 2008). Molecules, such as GUK-901 and SDH-
381 with their Papp coefficients for both directions being almost equal, can be 
practically transported without any influence of unidirectional active 
membrane transporters. Other compounds (GUK-982, 987 and GDH-375) 
showed efflux ratio ranging from 1 to 2, however this asymmetry in transport 
was insignificant. Moreover, molecules with such low ratio value usually tend 
to exhibit good CNS penetration in vivo (Summerfield et al. 2006). In order to 
determine the degree of active transport, another experiment with the use of 
efflux transporter inhibitors, such as verapamil which inhibits both P-
glycoprotein and BCRP (Breedveld et al. 2006), can be performed.
Regarding fluorescein permeability as simultaneous leakiness check, all 
compounds proved enhanced diffusion of FLU through cell monolayer in BL-
AP direction. FLU is commonly recognized by two classes of transporters 
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expressed in BBB and Caco-2 cells: MRPs and organic anion transport 
proteins (OATPs) (Sun, Miller and Elmquist, 2001). Interestingly, the MRP-2 
mediated efflux of FLU is stimulated by higher concentration of glucose 
(Hawkins et al. 2007); however this is not the case because of glucose level 
being same in all measurements. Another example of modification of FLU 
transport across membrane may be by inhibition of either MRP or OATP 
(using e.g. probenecid) (Sun, Miller and Elmquist, 2001). Therefore, it is safe 
to assume that these chemical substances somehow might activate 
transporters on luminal side of membrane, which leads to increased efflux of 
FLU. However, the exact mechanism of activation is unknown.
GUK-1007, which chemical structure differs from others by amide derived 
from primary amine, was highly metabolised and therefore was not 
detectable.
Before the compound reaches BBB, it has to overcome many obstacles 
(intestinal barrier, liver, kidneys), in which the presence of ABC transporters 
can affect pharmacokinetics of drugs and therefore influence anticipated 
drug absorption, distribution and excretion. Our tested compounds have 
been designed for oral administration and in this regard our results indicate 
good intestinal absorption. With the permeability rate ranging from 28.00 to
43.80 cm · s-1 x 10-6 we hypothesize that the tested compounds will be 
quantitatively absorbed from the intestine. (Breemen, Li 2005). However, not 
always the in vitro and in vivo results correlate; in vivo CNS penetration is 
determined not only by permeability and transporter activity, but also by 
unbound fraction in plasma (Summerfiel et al. 2006). Therefore, in vivo 
testing is needed in order to fully evaluate the CNS penetration and other 
pharmacokinetic properties of the tested compounds.
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7. Conclusion
The purpose of this thesis was to investigate the ability of several 
compounds, which may serve as new butyrylcholinesterase inhibitors to 
treat certain types of dementia in elderly patients, to penetrate through cell 
barriers in vitro. Our results suggest reliable transport ability across 
physiological barriers, such as intestinal and BBB, with permeability 
coefficients comparable to drugs commonly used in treatment of different 
CNS disorders such as epilepsy or depression. The involvement of ABC 
efflux transporters was also assed in order to predict the fate of compound 
after administration. Efflux ratios obtained indicate negligible or none efflux 
transporter influence on compound transport. However, the physiological 
rate of transport may be further affected by the degree of protein binding and 
also the rate of metabolism.
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8. List	of	abbreviations




AMT – adsorptive mediated transcytosis
AP - BL – apical to basolateral direction
ATCC – American tissue culture collection
ATP – adenosine triphosphate
BBB – blood-brain barrier
BChE - butyrylcholinesterase
BChEi – butyrylcholinesterase inhibitors
BCRP – breast cancer resistance protein
BL - AP – basolateral to apical direction
Caco-2 – human colon adenocarcinoma cell line
CNS – central nervous system
DMEM – Dulbecco’s minimum essential medium
DMSO – dimethyl sulfoxide
DPBS – Dulbecco’s phosphate buffer saline
FAAH – Fatty Acid Amide Hydrolase
FBS – fetal bovine serum
FLU – fluorescein
HPLC – high-performance liquid chromatography
LC-MS – analytical system comprised of liquid chromatography and mass 
spectrometry
MDCK – Madin-Darby canine kidney cell line
MRP – multidrug resistance-related protein
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MW – molecular weight
NMDA – N-methyl – D aspartate
OATP – organic anion transport protein
P-gp – P-glycoprotein
PAMPA – parallel artificial membrane permeability assay
Papp – apparent permeability coefficient
RMT – receptor mediated transcytosis
RPM – revolutions per minute
RSD – relative standard deviation
SD – standard deviation
TEER – transendothelial electrical resistance
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